JP2023536667A5 - - Google Patents
Info
- Publication number
- JP2023536667A5 JP2023536667A5 JP2023507979A JP2023507979A JP2023536667A5 JP 2023536667 A5 JP2023536667 A5 JP 2023536667A5 JP 2023507979 A JP2023507979 A JP 2023507979A JP 2023507979 A JP2023507979 A JP 2023507979A JP 2023536667 A5 JP2023536667 A5 JP 2023536667A5
- Authority
- JP
- Japan
- Prior art keywords
- tablet formulation
- formulation according
- approximately
- weight
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061050P | 2020-08-04 | 2020-08-04 | |
| US63/061,050 | 2020-08-04 | ||
| PCT/US2021/044295 WO2022031666A1 (en) | 2020-08-04 | 2021-08-03 | Formulations of triphenyl calcilytic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023536667A JP2023536667A (ja) | 2023-08-28 |
| JP2023536667A5 true JP2023536667A5 (https=) | 2024-08-13 |
| JP7827696B2 JP7827696B2 (ja) | 2026-03-10 |
Family
ID=77431430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023507979A Active JP7827696B2 (ja) | 2020-08-04 | 2021-08-03 | トリフェニルカルシリティック化合物の製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220040112A1 (https=) |
| EP (1) | EP4192438A1 (https=) |
| JP (1) | JP7827696B2 (https=) |
| KR (1) | KR20230106582A (https=) |
| CN (1) | CN116648243A (https=) |
| AR (1) | AR123147A1 (https=) |
| AU (1) | AU2021320147A1 (https=) |
| BR (1) | BR112023002107A2 (https=) |
| CA (1) | CA3188044A1 (https=) |
| IL (1) | IL300285A (https=) |
| MX (1) | MX2023001438A (https=) |
| TW (1) | TW202220642A (https=) |
| WO (1) | WO2022031666A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| AU2021343475A1 (en) * | 2020-09-18 | 2023-06-01 | Calcilytix Therapeutics, Inc. | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
| WO2024160842A1 (en) | 2023-01-30 | 2024-08-08 | Medizinische Universität Wien | Use of calcilytics for preventing or treating hypoparathyroidism associated with anterior neck surgery |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407097A (pt) | 2003-04-23 | 2006-01-24 | Japan Tobacco Inc | Antagonista do casr |
| EP1964548A1 (en) * | 2007-03-02 | 2008-09-03 | Novartis AG | Pharmaceutical compositions comprising a calcilytic agent |
| NZ595513A (en) * | 2009-03-26 | 2013-05-31 | Japan Tobacco Inc | Process for producing carboxylic acid compound |
| HRP20211752T1 (hr) * | 2010-04-07 | 2022-02-18 | Vertex Pharmaceuticals Incorporated | Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena |
| GB201217330D0 (en) * | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
| BR112020013073A2 (pt) | 2017-12-29 | 2020-12-01 | Biomarin Pharmaceutical Inc. | composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo |
| US20220288076A1 (en) | 2019-08-13 | 2022-09-15 | Dongguk University Industry-Academic Cooperation Foundation | Pharmaceutical composition for improving or treating post-surgical hypoparathyroidism and treatment method using the same |
| GB201918586D0 (en) * | 2019-12-17 | 2020-01-29 | Patterson James | Engineered platelets for targeted delivery of a therapeutic agent |
| KR20230106582A (ko) | 2020-08-04 | 2023-07-13 | 캘시리틱스 테라퓨틱스, 인코포레이티드 | 트리페닐 칼실리틱 화합물의 제형 |
| AU2021343475A1 (en) | 2020-09-18 | 2023-06-01 | Calcilytix Therapeutics, Inc. | Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) |
-
2021
- 2021-08-03 KR KR1020237007456A patent/KR20230106582A/ko active Pending
- 2021-08-03 BR BR112023002107A patent/BR112023002107A2/pt unknown
- 2021-08-03 MX MX2023001438A patent/MX2023001438A/es unknown
- 2021-08-03 EP EP21758555.3A patent/EP4192438A1/en active Pending
- 2021-08-03 CA CA3188044A patent/CA3188044A1/en active Pending
- 2021-08-03 WO PCT/US2021/044295 patent/WO2022031666A1/en not_active Ceased
- 2021-08-03 US US17/392,720 patent/US20220040112A1/en not_active Abandoned
- 2021-08-03 JP JP2023507979A patent/JP7827696B2/ja active Active
- 2021-08-03 AU AU2021320147A patent/AU2021320147A1/en active Pending
- 2021-08-03 CN CN202180066180.1A patent/CN116648243A/zh active Pending
- 2021-08-03 IL IL300285A patent/IL300285A/en unknown
- 2021-08-04 AR ARP210102174A patent/AR123147A1/es unknown
- 2021-08-04 TW TW110128669A patent/TW202220642A/zh unknown
-
2023
- 2023-06-29 US US18/216,536 patent/US12357576B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512117A5 (https=) | ||
| US20070036850A1 (en) | Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound | |
| JP2023536667A5 (https=) | ||
| JP2022542804A5 (https=) | ||
| US11260047B2 (en) | Formulations of AG10 | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| KR102555956B1 (ko) | 안정성이 향상된 라베프라졸을 유효성분으로 포함하는 경구용 속방형 제제 및 이의 제조방법 | |
| WO2022225489A1 (en) | A bilayer tablet formulation comprising amorphous dapagliflozin and metformin | |
| JP2023548855A5 (https=) | ||
| JP7585043B2 (ja) | レナリドミドを含む医薬組成物 | |
| US11730753B2 (en) | Stable pharmaceutical compositions comprising trifluridine and tipiracil hydrochloride | |
| US20210267908A1 (en) | Pharmaceutical compositions of rivaroxaban | |
| JP2024525954A5 (https=) | ||
| JP7355846B2 (ja) | 固形製剤 | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| JP2024503689A5 (https=) | ||
| KR102258372B1 (ko) | 베포타스틴의 방출 제어형 경구 제제 | |
| US12059419B2 (en) | Pharmaceutical composition comprising phthalazinone derivatives | |
| JP7423297B2 (ja) | 口腔内崩壊錠およびその製造方法 | |
| JP5065519B1 (ja) | 結晶性アトルバスタチンカルシウム含有錠剤の製造方法 | |
| US10034855B2 (en) | Solid composition of pyrrole carboxamide | |
| EP4140478A1 (en) | A solid pharmaceutical composition comprising sacubitril and valsartan | |
| WO2023027671A1 (en) | A solid pharmaceutical composition comprising sacubitril and valsartan | |
| EA045272B1 (ru) | Твердая фармацевтическая композиция на основе гидрохлорида луразидона для перорального применения | |
| JP2025017818A (ja) | ビラスチン含有錠剤及びその製造方法 |